摘要
目的通过运用益气活血法的代表方剂补阳还五汤对血管平滑肌细胞的干预,观察各组血管平滑肌细胞Rho激酶及TFmRNA、基质金属蛋白酶MMP-2mRNA、MMP-9mRNA的表达等指标的变化。方法将30只SD大鼠随机分为3组,一组为正常对照组,另两组为补阳还五汤低剂量对照组(10 g·kg^(-1))和补阳还五汤高剂量对照组(20 g·kg^(-1));AS模型大鼠30只随机分为模型组,补阳还五汤低剂量治疗组(10 g·kg^(-1))和补阳还五汤高剂量治疗组(20 g·kg^(-1))。给SD正常大鼠和AS模型大鼠口服不同浓度的补阳还五汤以制备含药大鼠血清,并在用含药大鼠血清保护体外培养的血管平滑肌细胞之后,检测血管平滑肌细胞Rho激酶mRNA、TFmRNA、MMP-2mRNA、MMP-9mRNA的表达。结果与模型对照组相比,各组补阳还五汤高剂量治疗组血管平滑肌细胞Rho激酶、TFmRNA、MMP-2mRNA、MMP-9mRNA的表达均降低。差异均有统计学意义(P<0.05,P<0.01)。结论补阳还五汤含药鼠血清可以通过抑制Rho激酶的活性,下调ROCK1、TF、MMP-2、MMP-9的mRNA的表达水平抑制血管平滑肌细胞增殖,从而抑制AS病变的形成和发展。
Objective To study the effect of representative Qi-tonifying and blood-activating formula Buyang Huanwu Decoction(补阳还五汤,BYHWD)on the atherosclerosis model in order to observe the vascular smooth muscle cell Rho kinase and expressions of TFmRNA,MMP-2 mRNA and MMP-9 mRNA.Method Thirty SD rats were randomly divided into three groups,one was the normal control group,the other two were BYHWD low-dose control group(10 g·kg^(-1))and BYHWD high-dose control group(20 g·kg^(-1)).Thirty AS model rats were randomly divided into model group,BYHWD low-dose treatment group(10 g·kg^(-1))and BYHWD high-dose treatment group(20 g·kg^(-1)).Gastric administration of normal SD rats and AS model rats by BYHWD with different concentrations were used to prepare drug-containing rat serum,and the drug-containing rat serum was used to protect vascular smooth muscle cells cultured in vitro.After that,expressions of smooth muscle cells Rho kinase mRNA,TFmRNA,MMP-2 mRNA,and MMP-9 mRNA were detected.Result Compared with the model control groups,the activity of Rho kinase and the expressions of TF mRNA,MMP-2 mRNA and MMP-9 mRNA in vascular smooth muscle cells of BYHWD high-dose treatment group decreased with significant statistical differences(P<0.05,P<0.01).Conclusion Drug-containing serum can inhibit the proliferation of vascular smooth muscle cells by down-regulating expressions of mRNA of ROCK1,TF,MMP-2,MMP-9 and p-MYPT1.
作者
张红珍
刘建春
王青
姜维佳
钟秉知
郭春兰
宋丽娟
高雅
周欣欣
石玉士
马存根
ZHANG Hongzhen;LIU Jianchun;WANG Qing;JIANG Weijia;ZHONG Bingzhi;GUO Chunlan;SONG Lijuan;GAO Ya;ZHOU Xinxin;SHI Yushi;MA Cungen(Shanxi University of Traditional Chinese Medicine,Taiyuan 030619,Shanxi,China;Chongqing University,Chongqing 400030,China;Datong University,Datong 037009,Shanxi,China)
出处
《中华中医药学刊》
CAS
北大核心
2021年第1期17-21,共5页
Chinese Archives of Traditional Chinese Medicine
基金
国家自然科学基金(81373532)
山西省黄芪资源产业化及产业国际化协同创新中心项目(HQXTCXZX2016-024)。